Please login to the form below

Not currently logged in
Email:
Password:

Almirall/ Nycomed COPD co-branding deal

Almirall and Nycomed have entered into a co-branding agreement for the commercialisation of roflumilast, a once-daily tablet for patients with chronic obstructive pulmonary disease, in Spain

Almirall and Nycomed have entered into a co-branding agreement for the commercialisation of roflumilast, the once-daily tablet for patients with chronic obstructive pulmonary disease (COPD), in Spain.

Roflumilast is an orally administered phosphodiesterase 4 (PDE4) enzyme inhibitor, and the first oral anti-inflammatory treatment for COPD.

Nycomed will receive an undisclosed upfront fee from Almirall, who will be exclusively promoting a second brand of roflumilast in Spain.

Luciano Conde, Almirall's chief operating officer, said: "This product, an entirely new class of treatment, has a strong strategic fit in our business and is fully complementary with other bronchodilator treatments in COPD such as our R&D product aclidinium bromide which is expected to be filed this year.

"We expect roflumilast to generate sales as of this year and could become one of Almirall's key products in the mid-term," he added.

5th May 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
AMICULUM Limited

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

COVID-19 is redefining the value of ‘critical jobs’: An opportunity for social care?
...
How to keep your weight under control during lockdown
...
Brands stepping up to show solidarity during COVID-19
The brands that are stepping up to show solidarity during COVID-19 will be those that are remembered long after pandemic passes....

Infographics